What Causes Fluctuations in CA-125?

CA-125 is one of the most commonly ordered blood markers in gynecology, yet its levels shift in response to a surprisingly wide range of conditions that have nothing to do with ovarian cancer. The protein, formally known as MUC16, sits on the surface of cells lining the abdomen, chest cavity, and reproductive organs. Anything that irritates, stretches, or inflames those surfaces can send more of it into the bloodstream. Understanding what drives these fluctuations matters because a single elevated reading, without context, can trigger unnecessary anxiety or further testing.

What CA-125 Actually Is

CA-125 is a large glycoprotein produced by cells on the surface of the ovaries, fallopian tubes, uterine lining, and the peritoneum (the membrane lining the abdominal cavity). It can be released, or “shed,” from these surfaces into the blood. In ovarian cancer, tumor cells produce it in large quantities, which is why it became a standard monitoring tool for that disease. But because MUC16 is expressed on so many normal tissue surfaces, the list of non-cancer triggers for elevated readings is long.¹

The conventional cutoff used in clinical practice is 35 U/mL. Levels above that are flagged as “elevated.” But this threshold was set decades ago for ovarian cancer screening, and it does not account for many of the normal and benign reasons a person’s CA-125 might sit above or below that line. Researchers have long recognized that the number on any single blood draw is less meaningful than the pattern of change over time.

The Menstrual Cycle

If you are premenopausal, where you are in your menstrual cycle can meaningfully shift your CA-125 reading. Levels tend to peak around the time of menstruation and drop to their lowest point mid-cycle. One study of premenopausal women found that CA-125 values during menses averaged roughly double those measured at mid-cycle.² A larger population study confirmed that CA-125 was significantly higher around the start and end of the cycle compared to mid-cycle, and about 5% of premenopausal women in the study had levels above 35 U/mL without any underlying disease.³

The mechanism appears tied to normal cyclical changes in the reproductive tract. As the uterine lining builds up and breaks down each month, the peritoneal surface is exposed to menstrual debris, which stimulates MUC16 shedding. Research tracking healthy women through their cycles found that CA-125 concentrations rose in parallel with the growth of the dominant follicle, suggesting hormonal regulation plays a direct role.⁴ The practical takeaway: if your doctor orders a CA-125 test and you are still menstruating, the timing within your cycle matters. A reading drawn on the first day of your period may look quite different from one drawn two weeks later.

Pregnancy and the Postpartum Period

Pregnancy creates its own distinctive pattern of CA-125 fluctuation. In the first trimester, levels can rise noticeably. A study of women who became pregnant after ovulation induction found that CA-125, which had been undetectable before pregnancy, rose during the first trimester in nearly all of them before dropping back to undetectable levels by the end of that trimester.⁵ This early spike likely reflects the rapid changes in the uterine lining as the embryo implants and the placenta develops.

Through the second and third trimesters, CA-125 tends to settle down. A study examining pregnant women without ovarian tumors found that serum levels remained stable and below 35 U/mL during most of pregnancy, but then rose again around the time of delivery and in the postpartum period.⁶ The delivery-related spike makes sense: the physical trauma of childbirth and the shedding of the placenta disturb the peritoneal and uterine surfaces. Anyone interpreting CA-125 results in a pregnant or recently postpartum woman needs to account for these normal surges.

Endometriosis

Endometriosis is one of the most common benign reasons for persistently elevated CA-125. In this condition, tissue similar to the uterine lining grows outside the uterus, often on the ovaries, fallopian tubes, and peritoneum. Each menstrual cycle, those implants become inflamed and bleed, irritating the peritoneal surface and driving up MUC16 production. Studies consistently show that CA-125 rises in step with disease severity: the higher the stage of endometriosis, the larger the lesions, and the more adhesions present, the higher the CA-125 tends to be.⁷⁸

What makes this tricky is that pain severity does not track neatly with CA-125 levels. A person with mild-appearing disease can be in significant pain with a normal reading, while someone with advanced disease and high CA-125 may have fewer symptoms. CA-125 correlates with the anatomical extent of the disease, not how much it hurts. This distinction matters when endometriosis patients see their CA-125 results and try to match them to how they feel.

Uterine Fibroids

Fibroids, the benign muscular growths of the uterus, are another frequently overlooked cause of elevated CA-125. More than a third of fibroid patients in one study had elevated levels before treatment, and there was a clear positive correlation between the total volume of fibroids and the concentration of CA-125 in the blood.⁹ When the uterus was removed or fibroids were medically shrunk with hormone therapy, CA-125 levels fell below even the range seen in healthy controls. The likely explanation is that large fibroids stretch and distort the uterine and peritoneal surfaces, prompting more MUC16 release.

Fluid Accumulation Anywhere in the Abdomen or Chest

One of the strongest and most underappreciated drivers of CA-125 is serous fluid accumulation, meaning fluid collecting in the abdominal cavity (ascites), around the lungs (pleural effusion), or in peripheral tissues (edema). The peritoneum is the body’s largest mesothelial surface, and when it is physically stretched by accumulating fluid, it ramps up production of MUC16. This is a mechanical effect, not a cancer signal.

Liver cirrhosis is a textbook example. In patients with cirrhosis and ascites, nearly all had elevated CA-125, with an average serum level around 321 U/mL. By contrast, cirrhosis patients without ascites almost never had elevated readings. Serum CA-125 correlated strongly with the amount of ascitic fluid, and when fluid was drained through paracentesis, CA-125 levels dropped sharply within days.¹⁰ A separate retrospective analysis confirmed that the elevation tracked with worsening ascites rather than with portal hypertension per se, reinforcing the idea that physical stretching of the peritoneum is the key trigger.¹¹

Heart failure produces the same pattern. When the heart struggles to pump effectively, fluid backs up into the lungs and abdomen. CA-125 levels correlate with clinical signs of congestion such as pulmonary edema, pleural effusion, and peripheral edema, and can spike during episodes of acute decompensated heart failure.¹² Cardiologists have actually started exploring CA-125 as a tool for gauging fluid overload, a far cry from the marker’s origins in oncology.

Autoimmune and Inflammatory Diseases

Systemic inflammatory conditions, particularly systemic lupus erythematosus (SLE), can push CA-125 into ranges that mimic cancer. SLE and related autoimmune syndromes are associated with CA-125 elevations, especially when the disease produces ascites or pleural effusion.¹³ Case reports describe lupus patients presenting with massive ascites and dramatically high CA-125 levels in a pattern called pseudo-pseudo Meigs’ syndrome, which can be clinically indistinguishable from ovarian cancer on initial assessment.¹⁴ The underlying mechanism circles back to the same theme: peritoneal irritation and fluid accumulation drive up MUC16 shedding regardless of whether cancer is present.

Surgery and Medical Procedures

Abdominal surgery itself causes a temporary surge in CA-125 that has nothing to do with the disease being treated. Studies found that post-operative CA-125 elevations occurred across a range of surgeries: in patients undergoing operations for ovarian cancer, uterine cancer, gastrointestinal cancer, and even benign gynecological conditions. The surgical procedure itself appeared responsible.¹⁵

The timing follows a consistent pattern. CA-125 peaks within a few hours of surgery and can remain elevated for up to three months. Even when preoperative levels were normal, more than 60% of patients developed postoperative elevations. The likely explanation is that cutting into and healing the peritoneum and omentum stimulates new production of MUC16 rather than simply releasing stored protein from damaged tissue.¹⁶ For oncologists monitoring ovarian cancer patients after debulking surgery, this means that early postoperative CA-125 readings are unreliable for gauging how much tumor was actually removed.

Non-Ovarian Cancers

While CA-125 is most closely associated with ovarian cancer, cancers originating in other organs can elevate it too. Lung cancer cells produce CA-125 in vitro, and the marker has shown potential relevance in breast and pancreatic cancers as well.¹⁷ In lung adenocarcinoma specifically, CA-125 levels increase with disease stage, and in advanced-stage patients, elevated CA-125 is an independent predictor of worse progression-free survival.¹⁸ Any cancer that involves the peritoneal surface, produces significant inflammation, or causes ascites or pleural effusion can raise CA-125 through the same mechanical and inflammatory pathways described above.

Demographic and Lifestyle Factors That Shift Baseline Levels

Even in healthy people with no disease, CA-125 varies based on factors that have nothing to do with pathology. A large prospective study of high-risk women found several demographic variables that significantly affected baseline CA-125:

Oral contraceptives: Premenopausal women currently using oral contraceptives had levels about 26% lower than non-users.
Race and ethnicity: Premenopausal women of Asian background had levels about 24% lower than non-Asian women. Among postmenopausal women, Black women had a 22% reduction compared to the reference group.
Smoking: Current smoking was associated with about 15% lower CA-125 in premenopausal women, and roughly 8% lower in postmenopausal women.
Irregular periods: Having irregular cycles corresponded to about 11% lower values compared to women with regular cycles.
Prior oophorectomy: Having both ovaries removed reduced predicted levels by about 18%, while removing one ovary had no impact.

These findings come from multivariate analysis controlling for confounding factors.¹⁹ A separate analysis from the large PLCO screening trial found that among postmenopausal women without ovarian cancer, mean CA-125 was higher with increasing age, ever use of hormone therapy, and a history of breast cancer, but lower in non-White women, women who had hysterectomy, current smokers, and those with obesity.²⁰

The takeaway is that two healthy women of different ages, body compositions, ethnic backgrounds, and medication use could have meaningfully different “normal” CA-125 values. A single fixed cutoff of 35 U/mL treats everyone the same, which is one reason it performs poorly as a screening tool in diverse populations.

Kidney Function Is Mostly a Non-Issue

You might wonder whether impaired kidney function causes CA-125 to accumulate in the blood because the kidneys cannot clear it. Researchers addressed this directly by measuring CA-125 in patients on dialysis. The vast majority of readings fell within the normal range for healthy women, and there was no apparent correlation between CA-125 levels and kidney function markers like creatinine or adequacy of dialysis. The study concluded that even severe kidney impairment is not itself a meaningful cause of CA-125 elevation.²¹ This is useful to know because kidney disease patients often have other complicating conditions, and clinicians can at least cross renal clearance off the list of potential explanations for an unexpected CA-125 result.

Why Trends Matter More Than Single Readings

Given how many things push CA-125 around, clinicians increasingly rely on serial measurements rather than any single value. The Risk of Ovarian Cancer Algorithm (ROCA) represents this philosophy in its most developed form. Instead of asking “is this reading above or below 35?”, ROCA establishes a woman’s personal baseline over several measurements and then watches for a change-point — a rapid rise from that baseline that fits the kinetic pattern of a growing tumor.²²

This approach is more efficient than a fixed cutoff because it accounts for the fact that each woman has her own normal baseline, and benign causes of elevation tend to produce different patterns than cancer. A person with endometriosis may consistently run a CA-125 of 50, but that value staying flat over years is a completely different signal than a jump from 15 to 50 in six months. ROCA incorporates baseline level, rate of change, and normal variability to maximize sensitivity while minimizing false alarms.²³

In ovarian cancer monitoring after treatment, a similar principle applies. Rather than waiting for CA-125 to cross back above 35 U/mL, researchers have found that a doubling from a patient’s post-treatment lowest value (the nadir) catches relapse earlier. In one study, a doubling from nadir detected about 85% of imaging-confirmed relapses compared to 67% detected by the 35 U/mL threshold alone. The doubling approach also gave a lead time of roughly two to three months before imaging showed the recurrence, whereas the fixed threshold often did not flag the problem until the scan was already positive.²⁴

Benign Ovarian Cysts and Tubal Inflammation

Benign ovarian cysts sometimes push CA-125 above 35 U/mL, which can cause alarm if the context is not considered. Interestingly, one study found that the size of the cyst itself did not correlate with CA-125 levels. Instead, the elevation appeared to be related to accompanying inflammation, particularly in the fallopian tubes. When researchers looked at the pathology of removed specimens, tubal abnormalities were a better explanation for the raised marker than the cyst dimensions.²⁵ This finding underscores a recurring theme: inflammation and peritoneal irritation are the real triggers, not the mere presence of a mass.

Adding Other Markers to the Mix

Because CA-125 fluctuates for so many reasons, researchers have looked into combining it with other biomarkers, particularly HE4, to improve diagnostic accuracy. HE4 is another protein often elevated in ovarian cancer, and together the two markers feed into a calculation called the Risk of Ovarian Malignancy Algorithm (ROMA). However, the evidence on whether this combination actually outperforms CA-125 alone is mixed. A prospective validation study found that ROMA and HE4 did not significantly improve detection of ovarian cancer compared to CA-125 by itself.²⁶ A more recent analysis of recurrence detection found that CA-125 and HE4 had comparable predictive value, with closely overlapping accuracy.²⁷ The search for a reliable partner biomarker continues, but for now CA-125 remains the central player in ovarian cancer monitoring, warts and all.